The CCNT1 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited bulk population of MES-OV human ovarian endometrioid carcinoma cells, in which the CCNT1 gene has been disrupted to create a loss-of-function model for cyclin T1. As a polyclonal knockout pool, these cells provide a genetically heterogeneous background that facilitates the study of CCNT1-dependent functions without clonal artifacts. This knockout product is particularly suited for investigating the role of cyclin T1 in transcriptional elongation, P-TEFb complex activity, and the regulatory networks that control RNA polymerase II pause release.
The MES-OV cell line originates from a human ovarian endometrioid adenocarcinoma and displays an adherent epithelial morphology, representing a well-characterized model of epithelial ovarian cancer. This cell line supports reproducible growth and is suitable for diverse assays, including drug sensitivity, proliferation, and migration analyses. Its ovarian endometrioid carcinoma background offers a clinically relevant system for investigating gene dysregulation and evaluating targeted therapeutics in this cancer subtype.
Cyclin T1 (CCNT1) is the regulatory subunit of P-TEFb, forming an active kinase complex with CDK9 that phosphorylates Ser2 of the RNA polymerase II CTD and negative elongation factors NELF-E and SPT5, facilitating productive transcriptional elongation. P-TEFb is regulated by reversible incorporation into the 7SK snRNP (containing HEXIM1 and LARP7), from which it can be released by BRD4. In ovarian cancer cells, MAPK/ERK signaling converges on P-TEFb to control immediate early gene expression. Additionally, HIV-1 Tat directly binds cyclin T1 to hijack P-TEFb for viral LTR transactivation.
Disruption of CCNT1 in MES-OV cells provides a unique model to study the role of transcriptional elongation in ovarian endometrioid carcinoma. Loss of cyclin T1 can reveal P-TEFb-dependent oncogenic programs and help dissect interactions with tumor-suppressive PML nuclear bodies. Moreover, this polyclonal knockout enables HIV-1 Tat transactivation studies in an epithelial context, broadening the utility for mechanistic investigations and inhibitor screening.
Typical applications include ChIP-qPCR for RNA Pol II occupancy, RNA-seq for transcriptome profiling, HIV-1 LTR-luciferase reporter assays, and cell-based functional assays such as proliferation, migration, and sensitivity to CDK9 inhibitors. These polyclonal knockout cells are well suited for high-throughput screening of P-TEFb-targeting compounds and for deciphering cyclin T1??s role in ovarian cancer biology. For further inquiries, please contact Ascent Research.
